Soligenix Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Soligenix, Inc. (SNGX)
NASDAQ:AMEX Investor Relations:
soligenix.com/investors
Company Research
Source: Yahoo! Finance
US$1.31 loss per share. All figures shown in the chart above are for the trailing 12 month (TTM) period Soligenix EPS Beats Expectations, Revenues Fall Short Revenue missed analyst estimates by 99%. Earnings per share (EPS) exceeded analyst estimates by 26%. Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 11% from a week ago. Risk Analysis It is worth noting though that we have found 6 warning signs for Soligenix (5 are a bit unpleasant!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodolog
Show less
Read more
Impact Snapshot
Event Time:
SNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNGX alerts
High impacting Soligenix, Inc. news events
Weekly update
A roundup of the hottest topics
SNGX
News
- Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024PR Newswire
- Soligenix Receives European Patent for Improved Production of Synthetic HypericinPR Newswire
- Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire
- Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial ResultsPR Newswire
- Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone [Yahoo! Finance]Yahoo! Finance
SNGX
Sec Filings
- 8/16/24 - Form 424B5
- 8/16/24 - Form 8-K
- 8/9/24 - Form 424B3
- SNGX's page on the SEC website